US Breast Cancer Drug Market Outlook 2022

Description: Around the corners of world, cancer has infused itself in every country, region and each habitable land present over earth. Cancer has become one of those nightmares which haunt every individual once in a lifetime this is because of the increasing incidence rates and no proper care available until now. Given the steady increase in global cancer incidence with its associated morbidity and mortality, together with the spiraling healthcare costs of treatment, there is increasing interest in this stringent disease.

Breast cancer is the second leading cause of mortality among women, after the Lung cancer. In United States it is the most common diagnosed form of cancer accounting for the ratio of one is to three. As most type of cancers originates from a starting lump, so is the breast cancer. It is the breast tissue where the tumor generates in lobules and ducts that can be classified into invasive and non-invasive stages. A woman living in the US has a 12.3%, or a 1 in 8, lifetime risk of being diagnosed with breast cancer. In 2016, invasive breast cancer will be diagnosed in about 246,660 women and 2,600 men. An additional 61,000 new cases of in situ breast cancer will be diagnosed in women.

US breast cancer market is conquered by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). It was approved in 2012 by the FDA for the treatment of or late stage metastatic HER2-positive breast cancer patients.

Moreover, compounds such as Protein bound paclitaxel, tamoxifen, vincristine, raloxifene, docetaxel and many more generic as well as branded drugs have shown positive results in reducing cancer progression and increasing life expectancy. Recently, branded drug such as Bevacizumab has seen preference among oncologists even though the drug has been advised to be removed from breast cancer indication. The market for metastatic breast cancer for now is highly fragmented between numerous drugs, radiation therapy and alternative therapies such as vitamin therapy, acupuncture, macrobiotic diets, homeopathy and herbal medication. Nano therapy via nano probe technology and various other areas of alternate treatment are under trials to check for their effectiveness in decreasing disease progression and arresting the cancerous cell growth by target specific tumor cell suppression.

Due to extensive research and development in treatment approaches for breast cancer. Breast cancer patients in US have a new surgical option that eliminates exposure to radioactive materials and offers a less invasive, alternative for cancer detection. This strategy has been approved by FDA and will be used to locate early stage tumors. The Sentimag technology platform is a magnetic surgical guidance probe used with nanoparticle tracers and other magnetic devices to more safely and easily determine the spread of cancer.

Historically, Herceptin has ruled the market in US and across the globe but due to its US patent expiration in 2019 its biosimilars might gain the same success stories. The driving forces behind the popularity of this drug are the increasing awareness of breast cancer by the means of several programs and screening aids. Another aspect is the emergence of targeted and combinational therapies. Drugs for the HER 2+ receptors such as Herceptin and Kadcyla can be administered as monotherapy or in the combination for the better survival rates. There are three specific medications that will be pushing this growth forward in breast cancer drug sales. These include; Novartis' Afinitor, Roche/Genentech's Perjeta, and trastuzumab-DM1. Afinitor has gained regulatory approval in Europe and the United States to market medication that treats hormone-receptor positive breast cancer, which is expected to raise this company's peak-year sales past US$ 1 Billion.

Ongoing clinical development of the drug Perjeta is also predicted to help it bring impressive sales through 2021. Targeted therapies are predicted to keep advancing the treatment of breast cancer. Breast cancer drug development is a hive of activity but despite the busy pipeline, forecast has been for the uptake of just three novel agents in this market through 2021. Moreover, two of these agents will penetrate only the HER2-positive market segment, which will continue to be dominated by Roche.

Indeed, Breast cancer is a difficult diagnosis to receive for any women, as these fears up for the low survival rates and every one in eight women develop the breast cancer throughout a lifetime. The healthcare sector and cancer drug market has focused on developing better treatments over the past years and new regimens are on the road to success.
"US Breast Cancer Drug Market Outlook 2022" Report Highlights:

- US Breast Cancer Tendencies
- US Breast Cancer Drug Market Outline
- US Breast Cancer Drug Market Dynamics
- Breast Cancer Risk Undercurrents
- US Breast Cancer Marketed Drugs Clinical Insight: 18 Drugs

Contents:

1. US Cancer Prevalence Rate
   1.1 Overview
   1.2 Glimpse of Past Cancer Incidences
   1.3 Current Drifts in Cancer Frequencies
   1.4 Estimated Future Cancer Occurrences

2. US Breast Cancer Tendencies
   2.1 Indication
   2.2 Breast Cancer Historical Incidences
   2.3 Recent inclinations in Breast Cancer
   2.4 Breast Cancer Frequencies over Age & Race

3. Breast Cancer Risk Undercurrents
   3.1 Hormonal Aspects
   3.2 Family History & Genetic Predisposition
   3.3 Cumulative Age & Elevated Risk
   3.4 Management of Breast Cancer

4. US Breast Cancer Drug Market Outline
   4.1 Topographical Arcade Sales
   4.2 HER-2 Positive Drug Market

5. US Breast Cancer Drug Market Dynamics
   5.1 Breast Cancer Market Accelerative Parameters
   5.2 Breast Cancer Market Challenges

6. US Breast Cancer Drug Market Future Aspects

7. Eribulin (Halaven)
   7.1 Clinical Introduction
   7.2 Brand Names
   7.3 Recording & Reporting Of Clinical Adverse Events

8. Trastuzumab Emtansine (Kadcyla)
   8.1 Clinical Introduction
   8.2 Brand Names
   8.3 Recording & Reporting Of Clinical Adverse Events

9. Palbociclib (Ibrance)
   9.1 Clinical Introduction
   9.2 Brand Names
   9.3 Recording & Reporting Of Clinical Adverse Events

10. Pertuzumab (Omnitarg & Perjeta)
    10.1 Clinical Introduction
    10.2 Brand Names
    10.3 Recording & Reporting Of Clinical Adverse Events

11. Gadobutrol (Gadavist, Gadovist & Gadovist 1.0)
    11.1 Clinical Introduction
    11.2 Brand Names
    11.3 Recording & Reporting Of Clinical Adverse Events
12. Lapatinib (Tykerb)
   12.1 Clinical Introduction
   12.2 Brand Names
   12.3 Recording & Reporting Of Clinical Adverse Events

13. Tamoxifen Oral Liquid (Soltamox)
   13.1 Clinical Introduction
   13.2 Brand Names
   13.3 Recording & Reporting Of Clinical Adverse Events

14. Fulvestrant (Faslodex)
   14.1 Clinical Introduction
   14.2 Brand Names
   14.3 Recording & Reporting Of Clinical Adverse Events

15. Anastrozole (Arimidex)
   15.1 Clinical Introduction
   15.2 Brand Names
   15.3 Recording & Reporting Of Clinical Adverse Events

16. Ixabepilone (Ixempra)
   16.1 Clinical Introduction
   16.2 Brand Names
   16.3 Recording & Reporting Of Clinical Adverse Events

17. Toremifene (Fareston)
   17.1 Clinical Introduction
   17.2 Brand Names
   17.3 Recording & Reporting Of Clinical Adverse Events

18. Letrozole (Femara)
   18.1 Clinical Introduction
   18.2 Brand Names
   18.3 Recording & Reporting Of Clinical Adverse Events

19. Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene))
   19.1 Clinical Introduction
   19.2 Brand Names

20. Exemestane (Aromasin)
   20.1 Clinical Introduction
   20.2 Brand Names
   20.3 Recording & Reporting Of Clinical Adverse Events

21. Vitamin B12 Fluorescent-Analogues (CobalaFluor Green & CobalaFluor Red)
   21.1 Clinical Introduction
   21.2 Brand Names

22. Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)
   22.1 Clinical Introduction
   22.2 Brand Names

23. Fluoxymesterone
   23.1 Clinical Introduction
   23.2 Recording & Reporting Of Clinical Adverse Events

24. Competitive Landscape
   24.1 Agilent Technologies
   24.2 AstraZeneca
   24.3 Bayer HealthCare Pharmaceuticals
   24.4 Bristol-Myers Squibb
   24.5 Eisai Co Ltd
24.6 Eli Lilly
24.7 Novartis
24.8 Onyx Pharmaceuticals
24.9 Orion
24.10 Perrigo
24.11 Pfizer
24.12 Roche

List of Figures:
Figure 1-1: Top Ten Countries in Cancer Incidence Trends
Figure 1-2: Global - Reported Deaths for the Leading Cancers in Men, 2012
Figure 1-3: US - Estimated Number of New Cancer Cases by Sex, 2016
Figure 2-1: Relationship between Age & Breast Cancer
Figure 2-2: Prevalence of Female Breast Cancer According to Ethnicity
Figure 3-1: Various Risk Factors Associated With Breast Cancer
Figure 4-1: Estimated Breast Cancer Deaths in North East Of US, 2016
Figure 4-2: HER-2 Positive Receptor & Herceptin
Figure 5-1: Accelerative Parameters of Breast Cancer Market
Figure 5-2: Current Challenges in Breast Cancer Therapeutics
Figure 8-1: Kadcyla - US Sales (Million US$), 2013-2022
Figure 8-2: Kadcyla - Global Sales (Million US$), 2013-2022
Figure 9-1: Ibrance - US Sales (Million US$), 2015-2022
Figure 9-2: Ibrance - Global Sales (Million US$), 2015-2022
Figure 10-1: Omnitarg- US Sales (Million US$), 2015-2022
Figure 10-2: Omnitarg / Perjeta - Global Sales (Million US$), 2015-2022
Figure 11-1: Gadavist - US Sales (Million US$), 2015-2022
Figure 11-2: Gadavist - Global Sales (Million US$), 2015-2022
Figure 12-1: Tykerb - US Sales (Million US$), 2015-2022
Figure 12-2: Tykerb - Global Sales (Million US$), 2015-2022
Figure 15-1: Arimidex - US Sales (Million US$), 2015-2022
Figure 15-2: Arimidex - Global Sales (Million US$), 2015-2022
Figure 16-1: Ixempra - US Sales (Million US$), 2015-2022
Figure 16-2: Ixempra - Global Sales (Million US$), 2015-2022
Figure 18-1: Femara - US Sales (Million US$), 2015-2022
Figure 18-2: Femara - Global Sales (Million US$), 2015-2022
Figure 24-1: Novartis - Clinical Pipeline
Figure 24-2: Roche - Clinical Pipeline

List of Tables:
Table 1-1: US - Estimated Number* of New Cancer Cases and Deaths by Sex, 2016
Table 1-2: US - Estimated Number* of New Cases for Selected Cancers by State, 2016
Table 1-3: US - Estimated Number* of Deaths for Selected Cancers by State, 2016

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: US Breast Cancer Drug Market Outlook 2022
Web Address: http://www.researchandmarkets.com/reports/3846247/
Office Code: SC2GQE83

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 1800</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>☐</td>
<td>USD 2100 + USD 56 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>☐</td>
<td>USD 2400 + USD 56 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 3600</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that timeframe to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World